Immunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 Shares

Immunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash acquired 20,000 shares of the stock in a transaction on Friday, June 13th. The stock was bought at an average cost of $0.83 per share, with a total value of $16,600.00. Following the completion of the transaction, the chairman now owns 36,032 shares in the company, valued at $29,906.56. This trade represents a 124.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Immunic Stock Up 1.9%

Shares of NASDAQ IMUX traded up $0.02 during mid-day trading on Monday, reaching $0.82. 670,798 shares of the company were exchanged, compared to its average volume of 885,357. Immunic, Inc. has a 1 year low of $0.56 and a 1 year high of $2.11. The firm has a 50-day moving average of $0.95 and a 200 day moving average of $1.04. The stock has a market cap of $78.62 million, a price-to-earnings ratio of -0.67 and a beta of 1.48.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, equities analysts forecast that Immunic, Inc. will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IMUX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Immunic in a report on Thursday, May 1st. William Blair restated an “outperform” rating on shares of Immunic in a research note on Friday, May 16th. B. Riley restated a “buy” rating and issued a $5.00 price objective (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Immunic currently has an average rating of “Buy” and a consensus target price of $11.60.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. purchased a new stake in shares of Immunic during the fourth quarter worth about $37,000. Renaissance Technologies LLC boosted its position in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. Barclays PLC purchased a new position in shares of Immunic in the 4th quarter valued at about $84,000. 683 Capital Management LLC increased its holdings in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.